[go: up one dir, main page]

NI200800169A - Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor - Google Patents

Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor

Info

Publication number
NI200800169A
NI200800169A NI200800169A NI200800169A NI200800169A NI 200800169 A NI200800169 A NI 200800169A NI 200800169 A NI200800169 A NI 200800169A NI 200800169 A NI200800169 A NI 200800169A NI 200800169 A NI200800169 A NI 200800169A
Authority
NI
Nicaragua
Prior art keywords
pain
treatment
benzo
fused heterocyclic
derivatives
Prior art date
Application number
NI200800169A
Other languages
English (en)
Inventor
B Reitz Allen
L Smith-Swintosky Virginia
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI200800169A publication Critical patent/NI200800169A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención es un método para el tratamiento del dolor que comprende la administración a un sujeto en necesidad del mismo una cantidad terapéuticamente eficaz de uno o más derivados novedosos de sulfamidas heterocíclicas benzo-fusionadas de la fórmula (I) y fórmula (II) como se describen en el presente documento. La presente invención también está dirigida a métodos para el tratamiento del dolor que comprenden la co-terapia con agente(s) anagésico(s) y un compuesto de la fórmula (I) o fórmula (II) como se describen aquí.
NI200800169A 2005-12-19 2008-06-18 Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor NI200800169A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75168605P 2005-12-19 2005-12-19
US77381206P 2006-02-15 2006-02-15
US11/612,071 US8716231B2 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain

Publications (1)

Publication Number Publication Date
NI200800169A true NI200800169A (es) 2012-05-28

Family

ID=38007332

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200800169A NI200800169A (es) 2005-12-19 2008-06-18 Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor

Country Status (26)

Country Link
US (1) US8716231B2 (es)
EP (1) EP1973540B1 (es)
JP (1) JP5190377B2 (es)
KR (1) KR20080077025A (es)
CN (1) CN101378746B (es)
AT (1) ATE447948T1 (es)
AU (1) AU2006331734B2 (es)
BR (1) BRPI0620018A2 (es)
CA (1) CA2634115C (es)
CR (1) CR10167A (es)
CY (1) CY1109732T1 (es)
DE (1) DE602006010442D1 (es)
DK (1) DK1973540T3 (es)
EA (1) EA016302B1 (es)
ES (1) ES2335699T3 (es)
HR (1) HRP20100007T1 (es)
IL (1) IL192100A0 (es)
MY (1) MY150903A (es)
NI (1) NI200800169A (es)
NO (1) NO20083005L (es)
NZ (1) NZ569040A (es)
PL (1) PL1973540T3 (es)
PT (1) PT1973540E (es)
RS (1) RS51249B (es)
SI (1) SI1973540T1 (es)
WO (1) WO2007075752A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EA200702558A1 (ru) * 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
CN102015674B (zh) * 2008-04-29 2014-10-29 Nsab神经研究瑞典公司分公司 多巴胺神经传递调节剂
US20110105462A1 (en) * 2008-04-29 2011-05-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
RU2010141964A (ru) * 2008-04-29 2012-06-10 НСАБ, Филиаль аф НьюроСерч Свиден АБ, Сверийе (DK) Модуляторы дофаминовой нейротрансмиссии
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2012314317A1 (en) 2011-09-29 2014-04-03 Janssen Pharmaceutica Nv Improved process for the preparation of sulfamide derivatives
JP2014528953A (ja) 2011-09-29 2014-10-30 ヤンセン ファーマシューティカ エヌ．ベー． スルファミド誘導体の調製プロセス
BR112016012833B1 (pt) 2013-12-19 2022-11-16 Eisai R&D Management Co. Ltd Agente terapêutico e/ou preventivo compreendendo derivado de 1-indansulfamida para dor
JP7439096B2 (ja) 2018-09-04 2024-02-27 田辺三菱製薬株式会社 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法
RU2712918C1 (ru) * 2019-08-01 2020-02-03 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ предотвращения острой боли при выполнении химического плевродеза после радикальных торакопластических операций онкологического характера

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527861A (en) 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (es) 1962-09-14
DE1211166B (de) 1962-11-20 1966-02-24 Ciba Geigy Verfahren zur Herstellung neuer Sulfamide
US3320314A (en) 1964-01-22 1967-05-16 Sandoz Ag Chlorobenzyl sulfamides
US3318952A (en) 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3383414A (en) 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
DE1542785A1 (de) 1965-07-24 1970-05-06 Bayer Ag Insekten- und milbenabweisende Mittel
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
DE2022370A1 (de) 1970-05-08 1971-12-02 Bayer Ag N-Fluordichlormethylthio-sulfamidsaeure-Derivate,Verfahren zu ihrer Herstellung und ihre mikrobizide und fungizide Verwendung
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5273993A (en) 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5189179A (en) 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
GB9026998D0 (en) 1990-12-12 1991-01-30 Glaxo Group Ltd Medicaments
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
GB9104890D0 (en) 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
IL103172A (en) 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2179733C (en) 1993-12-23 2007-03-27 Michael J. Costanzo Anticonvulsant pseudofructopyranose sulfamates
GB9417532D0 (en) 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
ATE204852T1 (de) 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
JP3235448B2 (ja) 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
AU7655796A (en) 1995-11-30 1997-06-19 C & C Research Laboratories Sulfamide derivatives
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
WO1998000124A1 (en) 1996-06-28 1998-01-08 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US6071537A (en) 1996-06-28 2000-06-06 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating obesity
DE69717281T2 (de) 1996-08-14 2003-09-04 G.D. Searle & Co., Chicago Kristalline form von 4-[5-methyl-3-phenylisoxazol-4-yl]benzolsulfonamid
EP0942752B1 (en) 1996-08-23 2005-04-20 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
WO1998015270A1 (en) 1996-10-08 1998-04-16 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5935933A (en) 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
ATE279919T1 (de) 1997-08-15 2004-11-15 Carolyn Ann Fairbanks Agmatin für die behandlung neuropathischer schmerzen
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
UA65607C2 (uk) 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
DK72798A (da) 1998-05-28 1998-05-28 Novo Nordisk As Treatment of GABA-uptake related disorders
WO2000001376A2 (en) 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
TR200102711T2 (tr) 1999-01-19 2001-12-21 Ortho-Mcneil Pharmaceutical, Inc. Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
AR022321A1 (es) 1999-01-21 2002-09-04 Ortho Mcneil Pharm Inc Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
CZ20013061A3 (cs) 1999-02-24 2002-06-12 University Of Cincinnati Pouľití sulfamátových derivátů pro léčbu poruch kontroly impulsů
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
MXPA01010218A (es) 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
US6583172B1 (en) 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
WO2000066109A2 (en) 1999-05-04 2000-11-09 Edwards Keith R Intravenous valproate for acute treatment of migraine headache
ES2542891T3 (es) 1999-06-14 2015-08-12 Vivus, Inc. Terapia de combinación para el tratamiento de apnea del sueño asociada con la obesidad
AU782759B2 (en) 1999-08-20 2005-08-25 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
FR2803848B1 (fr) 2000-01-19 2002-02-15 Adir Nouveaux derives de benzenesulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PL365680A1 (en) 2000-07-07 2005-01-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US7256184B2 (en) 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
EP1397136A1 (en) 2001-05-25 2004-03-17 Queen's University At Kingston Heterocyclic beta-aminoacids and their use as anti-epileptogenic agents
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
RU2246727C2 (ru) 2003-02-12 2005-02-20 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева (НИПИ) Способ диагностики доклинической стадии эпилепсии
RU2226357C1 (ru) 2003-02-12 2004-04-10 Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева Способ диагностики эпилепсии у пациентов с доклинической стадией болезни
US7425631B2 (en) 2003-04-10 2008-09-16 Amgen Inc. Compounds and methods of use
DE60326773D1 (de) 2003-04-16 2009-04-30 Smithkline Beecham Corp Peptid-deformylase-hemmer
WO2004093912A1 (ja) 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. 好中球性炎症疾患の予防および／または治療剤
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
US6949518B1 (en) 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US7095584B2 (en) * 2003-08-29 2006-08-22 Donaldson Company, Inc. Integrated chemical breather filter with high and low pressure surfaces
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006010008A1 (en) 2004-06-22 2006-01-26 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
HRP20120327T1 (hr) 2004-07-28 2012-05-31 Janssen Pharmaceutica Nv Supstituirani indolil alkil amino derivati kao novi inhibitori histonske deacetilaze
US20060276528A1 (en) 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
AU2005277134A1 (en) 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
KR20080009295A (ko) 2005-04-22 2008-01-28 와이어쓰 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
EA200702558A1 (ru) 2005-05-20 2008-06-30 Янссен Фармацевтика Н. В. Способ получения производных сульфамида
US20070155824A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2007137164A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy and related disorders
CA2711466A1 (en) 2008-01-07 2009-07-16 Janssen Pharmaceutica N.V. Process for the preparation of sulfamide derivatives
US20090247618A1 (en) 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
US20090247617A1 (en) 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives

Also Published As

Publication number Publication date
PT1973540E (pt) 2010-01-28
SI1973540T1 (sl) 2010-03-31
US20070155822A1 (en) 2007-07-05
JP2009520035A (ja) 2009-05-21
JP5190377B2 (ja) 2013-04-24
NO20083005L (no) 2008-09-16
PL1973540T3 (pl) 2010-04-30
IL192100A0 (en) 2009-08-03
MY150903A (en) 2014-03-14
WO2007075752A1 (en) 2007-07-05
ATE447948T1 (de) 2009-11-15
EP1973540B1 (en) 2009-11-11
AU2006331734A1 (en) 2007-07-05
HRP20100007T1 (hr) 2010-02-28
DE602006010442D1 (de) 2009-12-24
CY1109732T1 (el) 2014-09-10
DK1973540T3 (da) 2010-02-01
CN101378746B (zh) 2013-07-17
RS51249B (sr) 2010-12-31
CA2634115C (en) 2014-11-18
EA200870091A1 (ru) 2009-12-30
ES2335699T3 (es) 2010-03-31
EA016302B1 (ru) 2012-04-30
BRPI0620018A2 (pt) 2011-10-25
KR20080077025A (ko) 2008-08-20
CN101378746A (zh) 2009-03-04
US8716231B2 (en) 2014-05-06
AU2006331734B2 (en) 2012-12-20
CR10167A (es) 2009-01-16
HK1125039A1 (en) 2009-07-31
EP1973540A1 (en) 2008-10-01
NZ569040A (en) 2011-04-29
CA2634115A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CO6351742A2 (es) Compuestos organicos para la cicatrizacion de heridas
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CR10164A (es) Uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de obesidad
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
DOP2013000004A (es) Agentes terapeuticos 976
UY30034A1 (es) Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento del dolor
CL2009001327A1 (es) Compuestos heterociclo derivados de 3-oxoisoindolin-1-carboxamida; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento del dolor.
UY30038A1 (es) Uso de derivaods heterociclicos benzo-fusionados de sulfamida para el tratamiento de adiccion y abuso de sustancias
UY30039A1 (es) Uso de derivados heterociclicos benzo-fusionados para el tratamiento de la mania y el trastorno bipolar
CO6491023A2 (es) Uso de la combinacion de teriflunomida e interferon beta para el tratamiento de la esclerosis multiple
UY30155A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento de mania y trastorno bipolar